Hologic Awarded $4.8 Million in Patent Infringement Lawsuit against Minerva Surgical

MARLBOROUGH, Mass., July 27, 2018 /PRNewswire/ -- Hologic, Inc. (Nasdaq: HOLX) announced today that a jury in the U.S. District Court for the District of Delaware awarded Hologic $4.8 million in damages for Minerva Surgical's infringement of two Hologic patents related to endometrial ablation technology.

On June 28, 2018, the Court ruled that Minerva's endometrial ablation system infringes U.S. Patents 6,872,183 and 9,095,348. The Court also rejected all of Minerva's defenses to infringement. As a result of these decisions, Hologic will seek an injunction prohibiting Minerva from further manufacturing or selling the infringing device in the United States. Damages will continue to accrue until Minerva ceases its infringing conduct.

In November 2015, Hologic brought suit against Minerva alleging that Minerva's endometrial ablation system infringes several Hologic patents. The patents relate to technology used in the company's NovaSure endometrial ablation procedure, a market-leading treatment for abnormal uterine bleeding. In 2004, Hologic acquired the patents through its acquisition of Novacept, Inc. Former Novacept executive Csaba Truckai founded Minerva four years later. Minerva then developed and commercialized its endometrial ablation device, which the Court found incorporated the same patented technology that Novacept sold to Hologic.

"We are extremely pleased with the Court's ruling and the jury's verdict, which together validate Hologic's assertions of patent infringement by Minerva Surgical and recognize the value of our intellectual property," said Sean Daugherty, President of GYN Surgical Solutions at Hologic. "As the maker of the NovaSure system, we are committed to delivering best-in-class products backed by strong clinical data for our customers and their patients."

About Hologic

Hologic, Inc. is an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment.  For more information on Hologic, visit www.hologic.com.

Hologic, NovaSure, The Science of Sure, and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries. All other trademarks, registered trademarks, and product names are the property of their respective owners.

Forward-Looking Statements

This news release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic products. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient, as the actual effect of the use of the products can only be determined on a case-by-case basis. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such data or statements are based.

Media Contact:
Jane Mazur
508.263.8764 (direct)
585.355.5978 (mobile)
[email protected]

Investor Contact:
Michael Watts
858.410.8588
[email protected]

SOURCE Hologic, Inc.

Related Links

http://www.hologic.com

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED